TABLE 1.

Antibacterial activities of LJC 11,036 against clinical isolates of gram-positive bacteria

Organism (no. of strains)	Drug	MICa (μg/ml)
		Range	50%	90%
S. aureus
MSSA (53)	LJC 11,036	≤0.006–0.025	0.025	0.025
	Imipenem	0.013–0.2	0.025	0.025
	Faropenem	0.1–0.39	0.2	0.2
	Cefdinir	0.05–3.13	0.39	0.39
	Levofloxacin	0.1–3.13	0.39	0.39
MRSA (53)	LJC 11,036	0.2–12.5	6.25	12.5
	Imipenem	0.1–100	25	50
	Faropenem	0.78–>100	>100	>100
	Cefdinir	6.25–>100	>100	>100
	Levofloxacin	0.39–>100	50	>100
S. epidermidis (53)	LJC 11,036	0.013–12.5	0.1	6.25
	Imipenem	0.013–50	0.1	50
	Faropenem	0.05–>100	0.1	>100
	Cefdinir	0.025–>100	0.39	>100
	Levofloxacin	0.2–25	0.78	25
S. pneumoniae
PSSP (24)	LJC 11,036	≤0.006–0.025	≤0.006	≤0.006
	Imipenem	≤0.006–0.013	≤0.006	0.013
	Faropenem	≤0.006–0.05	0.013	0.025
	Cefdinir	0.025–0.39	0.05	0.2
	Levofloxacin	0.39–3.13	1.56	1.56
	Benzylpenicillin	≤0.006–0.05	0.025	0.05
PRSP (28)	LJC 11,036	≤0.006–0.2	0.05	0.1
	Imipenem	0.013–0.78	0.2	0.39
	Faropenem	0.05–0.78	0.39	0.39
	Cefdinir	0.1–6.25	1.56	3.13
	Levofloxacin	0.78–>12.5	1.56	12.5
	Benzylpenicillin	0.1–3.13	0.78	1.56
S. pyogenes (19)	LJC 11,036	≤0.006	≤0.006	≤0.006
	Imipenem	≤0.006	≤0.006	≤0.006
	Faropenem	≤0.006–0.025	0.025	0.025
	Cefdinir	≤0.006–0.013	0.013	0.013
	Levofloxacin	0.78–3.13	0.78	3.13

^aAgar dilution method.